Keith Newby, MD
Cardiovascular Disease · Norfolk, VANPI 1609809623
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $86,000 of the $89,976 with a category attached, or 95.6%. Philips North America LLC accounts for 95.6% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $30,245, more than ten times the $489 reported in 2019. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $573.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$86K
- Medtronic$1K
- Amgen$354
- Scpharmaceuticals Inc.$293
- Arbor Pharmaceuticals, Inc.$231
- Novartis$216
- plus $1K from 26 others
What the payments were for
- Consulting fees$86,00096%
- Travel & lodging$1,1401%
- Food & beverage$2,6673%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 4 | $86,020 |
| Medtronic | 20 | $1,388 |
| Amgen | 22 | $354 |
| Scpharmaceuticals Inc. | 15 | $293 |
| Arbor Pharmaceuticals, Inc. | 12 | $231 |
| Novartis | 11 | $216 |
| AstraZeneca | 10 | $165 |
| Cvrx, Inc. | 1 | $159 |
| Bardy Diagnostics, Inc. | 8 | $114 |
| Boehringer Ingelheim | 6 | $110 |
| Johnson & Johnson | 8 | $108 |
| Astellas Pharma US Inc | 3 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Boston Scientific | 3 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Vital Connect, Inc | 2 | $55 |
| Baxter Healthcare | 1 | $53 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| AbbVie(2 entities) | 2 | $35 |
| Merck | 2 | $34 |
| Medicomp Inc | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Pfizer | 2 | $30 |
| Novo Nordisk | 2 | $28 |
| Braemar Manufacturing, LLC | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Preventice Services, LLC | 1 | $19 |
| Gilead | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (5044) MCOT$60,000
- (7999) SRC Undivided$26,000
- Barostim Neo System$159
How this compares
$89,976 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 717 | $623,952 |
| EntrestoSacubitril/Valsartan | 368 | $398,503 |
| FarxigaDapagliflozin Propanediol | 304 | $261,238 |
| XareltoRivaroxaban | 225 | $229,509 |
| JardianceEmpagliflozin | 304 | $224,079 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 88 | $35,604 |
| Nifedipine ErNifedipine | 843 | $18,268 |
| Repatha SureclickEvolocumab | 26 | $15,153 |
| DapagliflozinDapagliflozin Propanediol | 25 | $15,133 |
| Flecainide Acetate | 301 | $13,552 |
| BrilintaTicagrelor | 11 | $10,835 |
| Midodrine Hcl | 85 | $9,815 |
| Bumetanide | 188 | $6,207 |
| Ranolazine ErRanolazine | 45 | $4,583 |
| Amiodarone Hcl | 282 | $4,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $623,952717 claims |
| NovartisEntresto | $216 | $398,503368 claims |
| AstraZenecaFarxiga, Brilinta | $165 | $272,072315 claims |
| Johnson & JohnsonXarelto | $108 | $229,509225 claims |
| Boehringer IngelheimJardiance | $110 | $224,079304 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $231 | $35,60488 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Norfolk
- Cyrus HadadiNorfolk$360K
- Joshua CohenNorfolk$78K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.